It's happening again.
In early September, a cluster of unexplained child deaths in a small town in Madhya Pradesh sent local health workers scrambling. At least 11 victims - aged one to six - had died within days of taking a common cough syrup. Officials tested everything from drinking water to mosquitoes before the truth emerged: their kidneys had failed.
Weeks later, a state laboratory in the southern city of Chennai confirmed the worst. The syrup in question contained 48.6% diethylene glycol, a toxic industrial solvent that should never be found in medicine.
The horror wasn't confined to Madhya Pradesh. In neighbouring Rajasthan state, the deaths of two young children after consuming a locally-made Dextromethorphan syrup sparked outrage and a government investigation.
Over the years, diethylene glycol in Indian-made cough syrups has claimed dozens of young lives, with 2023 linking contaminated syrups to the deaths of 70 children in The Gambia and 18 in Uzbekistan.
This pattern of abuse and mismanagement of cough syrups reflects a fragmented drug market and a weak regulatory system struggling to oversee countless low-cost syrups produced by smaller manufacturers and sold over the counter.
Days after the latest child deaths, India's health ministry urged 'rational' use of such medicines, suspending and banning sales while announcing an investigation.
The Indian cough syrup market, expected to balloon from $262.5 million in 2024 to $743 million by 2035, reveals a troubling fascination with these medications, often viewed as quick relief solutions despite their risks. As increasing air pollution worsens respiratory issues, reliance on cough syrups persists, revealing the challenges within India's healthcare system, especially in rural areas.
Experts emphasize that parents and healthcare professionals alike need education on the correct use of cough medicines, advocating for a crucial shift away from the cultural reliance on syrups and towards better healthcare practices.
In early September, a cluster of unexplained child deaths in a small town in Madhya Pradesh sent local health workers scrambling. At least 11 victims - aged one to six - had died within days of taking a common cough syrup. Officials tested everything from drinking water to mosquitoes before the truth emerged: their kidneys had failed.
Weeks later, a state laboratory in the southern city of Chennai confirmed the worst. The syrup in question contained 48.6% diethylene glycol, a toxic industrial solvent that should never be found in medicine.
The horror wasn't confined to Madhya Pradesh. In neighbouring Rajasthan state, the deaths of two young children after consuming a locally-made Dextromethorphan syrup sparked outrage and a government investigation.
Over the years, diethylene glycol in Indian-made cough syrups has claimed dozens of young lives, with 2023 linking contaminated syrups to the deaths of 70 children in The Gambia and 18 in Uzbekistan.
This pattern of abuse and mismanagement of cough syrups reflects a fragmented drug market and a weak regulatory system struggling to oversee countless low-cost syrups produced by smaller manufacturers and sold over the counter.
Days after the latest child deaths, India's health ministry urged 'rational' use of such medicines, suspending and banning sales while announcing an investigation.
The Indian cough syrup market, expected to balloon from $262.5 million in 2024 to $743 million by 2035, reveals a troubling fascination with these medications, often viewed as quick relief solutions despite their risks. As increasing air pollution worsens respiratory issues, reliance on cough syrups persists, revealing the challenges within India's healthcare system, especially in rural areas.
Experts emphasize that parents and healthcare professionals alike need education on the correct use of cough medicines, advocating for a crucial shift away from the cultural reliance on syrups and towards better healthcare practices.
